Wegovy is now available as a once-daily pill, offering a needle-free option for people who prefer oral medication
GLP-1 medications have been shown to help people lose a significant percentage of body weight when paired with a healthy diet and regular exercise
SUSTAIN-6 evaluated once-weekly semaglutide versus placebo in patients at moderate and high cardiovascular risk with type 2 diabetes, showing a 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95)
Keeping track of your food intake and staying within your caloric needs can help you navigate this transition successfully
If you are using Ozempic, Wegovy, Mounjaro, or Zepbound, this section applies to you
This is the most common complaint in patient surveys about GLP-1 access (Luo et al., JAMA Network Open 2024)